Back to Search

CHRISTOPHER SLAPAK, MD

MD

Hematology & Oncology Physician

NPI: 1164567871Individual

Specialties, Licenses & Credentials

Hematology & Oncology PhysicianPrimary

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

01045789A(IN)

Research & Publications (12)

Reversal of multidrug resistance with LY335979: functional analysis of P-glycoprotein-mediated transport activity and its modulation in vivo.
PMID 11452726·J Clin Pharmacol·2001
6-review
Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
PMID 18519780·Clin Cancer Res·2008
3-trial
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
PMID 17389337·J Clin Oncol·2007
3-trial
Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours.
PMID 15809877·Cancer Chemother Pharmacol·2005
3-trial
Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters.
PMID 15006547·Biochem Pharmacol·2004
7-preclinical
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
PMID 15172981·Cancer Res·2004
8-other
A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy.
PMID 15161679·Clin Cancer Res·2004
3-trial
Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
PMID 15534095·Clin Cancer Res·2004
3-trial
A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells.
PMID 11774257·Int J Cancer·2002
8-other
Identification and characterization of the canine multidrug resistance-associated protein.
PMID 12516967·Mol Cancer Ther·2002
7-preclinical
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies.
PMID 12473580·Clin Cancer Res·2002
3-trial
Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells.
PMID 11331075·Biochem Pharmacol·2001
8-other

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
THE WISHARD HOSPITAL HEMATOLOGY CLINIC, 1050 WISHARD BLVD
INDIANAPOLIS, IN 46202

Location

Practice Location

THE WISHARD HOSPITAL HEMATOLOGY CLINIC, INDIANAPOLIS, IN
(317) 630-7175

Quick Facts

NPI
1164567871
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
12

Are you this provider?

Claim Your Profile